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Prime editors (PEs) mediate genome modification without utilizing double-stranded DNA breaks 36 
or exogenous donor DNA as a template. PEs facilitate nucleotide substitutions or local insertions 37 
or deletions within the genome based on the template sequence encoded within the prime editing 38 
guide RNA (pegRNA). However, the efficacy of prime editing in adult mice has not been 39 
established. Here we report an NLS-optimized SpCas9-based prime editor that improves genome 40 
editing efficiency in both fluorescent reporter cells and at endogenous loci in cultured cell lines. 41 
Using this genome modification system, we could also seed tumor formation through somatic cell 42 
editing in the adult mouse. Finally, we successfully utilize dual adeno-associated virus (AAVs) for 43 
the delivery of a split-intein prime editor and demonstrate that this system enables the correction 44 
of a pathogenic mutation in the mouse liver. Our findings further establish the broad potential of 45 
this new genome editing technology for the directed installation of sequence modifications in vivo, 46 
with important implications for disease modeling and correction. 47 
 48 
Introduction 49 
Disease-associated genetic variations, including deletions, insertions and base substitutions, 50 
require precise gene correction strategies that are both robust and flexible1. Homology-direct 51 
repair (HDR) enables precise genome editing through an exogenous donor DNA. However, HDR 52 
is inefficient in most therapeutically relevant cell types, especially in post-mitotic cells2-4. Base 53 
editing enables efficient nucleotide transitions without inducing double-strand breaks (DSBs)5. 54 
However, targeted nucleotide transversions, deletions and insertions are not easily facilitated by 55 
well-established editing systems. In addition, depending on the local sequence context, base 56 
editing systems can also convert “bystander” nucleotides within the same editing window, which 57 
may be mutagenic, leading to the creation of unproductive or counter-productive alleles.        58 
 59 
The prime editor (PE) is a new genome editing tool that can produce template-directed local 60 
sequences changes in the genome without the requirement for a DSB or exogenous donor DNA 61 
templates 6. A PE comprises a fusion protein consisting of a catalytically impaired SpCas9 nickase 62 
(H840A) fused to an engineered reverse transcriptase (RT). A prime editing guide RNA (pegRNA) 63 
targets the PE to the desired genomic sequence and encodes the primer binding site (PBS) and 64 
reverse transcriptase template to enable the RT to copy the new genetic information into the target 65 
genomic locus 6. Prime editing enables nucleotide conversion and targeted sequence insertions 66 
and deletions based on the RT template sequence encoded within the pegRNA6. PE2 harbors 67 
five mutations within the M-MLV RT that improve editing efficiency6. PE3 uses an additional 68 
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sgRNA to direct SpCas9H840A to nick the non-edited DNA strand to encourage the edited strand 69 
to be utilized as a repair template by DNA repair factors, leading to further increases in editing 70 
efficiency6.   71 
 72 
The ability to precisely install or correct pathogenic mutations regardless of their composition 73 
makes prime editing an intriguing approach to perform somatic genome editing in model 74 
organisms to study disease processes or to utilize for therapeutic applications. Previous studies 75 
have used prime editing to recode loci in cultured cells6, plants7, stem cells8, 9, and mouse 76 
zygotes10, 11. However, PE delivery in adult animals has not yet been described. In this study, we 77 
report a nuclear localization signal sequence optimized PE2 (referred to as PE2*) with higher 78 
editing efficiency than PE2. We demonstrate that PE2* enables somatic genome editing in the 79 
liver of adult mice, where it can correct a pathogenic disease allele or introduce a directed 80 
mutation to drive tumor formation to facilitate cancer modeling. The size of a prime editor 81 
precludes its packaging in a single AAV vector. We show that dual AAV-mediated delivery of a 82 
split-intein prime editor is functional in vivo for gene editing in the mouse liver. These data 83 
demonstrate the feasibility of employing PE in vivo for the targeted, precise alteration of genomic 84 
sequence with potential utility both in model organisms and as a therapeutic modality. 85 
 86 
Results 87 
Optimized nuclear localization signal sequence composition improves prime editing  88 
 89 
PEs have the remarkable ability to introduce a variety of different types of sequence alterations 90 
into the genome. Their editing efficiency is influenced by a variety of different parameters (PBS 91 
length, position of the RT initiation site relative to the desired sequence alteration, composition of 92 
the desired sequence alteration, relative position of the alternate strand nick, etc.). Even under 93 
optimal conditions the incorporation rate of the desired edit into the genome is incomplete 6. 94 
Previously, we and others have noted that the composition and number of nuclear localization 95 
signal (NLS) sequences within a Cas9 effector can influence its efficiency of genome editing3, 12-96 
16. The original PE2 contains two SV40 NLS sequences 6, which can be suboptimal for maximizing 97 
editing rates by SpCas9 protein-sgRNA complexes12. In transient transfection assays of original 98 
PE2, we observed incomplete nuclear localization based on immunofluorescence: ~60% of the 99 
protein is present in the nucleus in U2OS cells and ~85% is present in the nucleus in HeLa cells; 100 
(Supplementary Fig. S1). We found that addition of a N-terminal c-Myc NLS17 and C-terminal 101 
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variant bipartite SV40 NLS (vBP-SV40)18 gives rise to nearly complete nuclear localization of the 102 
prime editor (PE2*) (Fig. 1a, Supplementary Fig. S1c,d).  103 
 104 
In parallel, we constructed PE2* frameworks using the orthogonal Staphylococcus aureus 105 
(SaCas9) nickase (N580A)19 to replace the SpCas9 nickase (H840A). To expand the potential 106 
targeting range of these alternate prime editors systems, we utilized both the standard SaCas9 107 
backbone that recognizes an NNGRRT PAM (SaPE2*)19 and the SaCas9KKH variant that broadens 108 
the targeting to an NNNRRT PAM (SaKKHPE2*)20 (Fig. 1a). By immunofluorescence staining using 109 
the incorporated 3xHA-tag we observed that SaPE2* or SaKKHPE2* proteins were localized to the 110 
nucleus (Supplementary Fig. S1a,b).  111 
 112 
To determine whether the observed improvements in nuclear localization translate into increases 113 
in editing efficiency, we evaluated the rate of nucleotide conversion for PE2 and PE2* in HEK293T 114 
mCherry reporter cells that contains a premature TAG stop codon that prevents translation of a 115 
functional protein (Supplementary Fig. S2a,d). PE2 and PE2* were programmed with a pegRNA 116 
designed to revert the TAG codon to CAG and delivered without and with different nicking sgRNAs. 117 
3 days after transfection, we performed flow cytometry to quantify prime-editing efficiency. PE2* 118 
produced a 1.5-1.6 fold increase in editing efficiency (14.3% to 26.4%) relative to PE2 (9.2% to 119 
16.5%; Fig. 1b). A compatible PAM is also present for SaKKHPE2* within the reporter to evaluate 120 
nucleotide conversion rates, with which we observed more modest editing efficiencies (1.8% to 121 
4.7%). All PE systems displayed lower editing activity than an adenine base editor system 122 
(ABEmax)13 for restoration of reporter function (Fig. 1b).  123 
 124 
Next, we tested the efficiency for generating a targeted deletion using PE2, PE2* and SaKKHPE2* 125 
in an HEK293T reporter line that can quantify both precise deletions and indel formation. This 126 
reporter design shares similarities to the traffic light reporter system 21, 22. A precise deletion of 127 
47bp will remove a sequence insertion disrupting GFP expression, whereas indels that produce 128 
a particular reading frame alteration restore mCherry expression (Supplementary Fig. S2b,d). 129 
PE2* produced a 1.6-1.9 fold increase in the level of precise deletions (5.6%-11.3%) compared 130 
to PE2 (3.0%-7.3%; Fig. 1c). The relative level of undesired indel formation was roughly 131 
proportional to the overall activity levels for PE2 and PE2*. We also observed that SaKKHPE2* 132 
could generate precise 47bp deletion with efficiencies ranging from 1.3% to 4.2% (Fig. 1c).  133 
 134 
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Finally, we tested the efficiency for generating a targeted insertion using PE2, PE2* and 135 
SaKKHPE2* in a different HEK293T reporter line (TLR-MCV1) that can quantify both precise 136 
insertions and indel formation23. A targeted, precise replacement of 39bp disruption sequence 137 
with a 18bp missing sequence element can restore GFP expression, whereas indels that produce 138 
a different reading frame alteration restore mCherry expression (Supplementary Fig. S2c,d). 139 
PE2* led to a 1.7 to 2.1-fold increase in the level of precise insertions (5.5%- 11.6%) compared 140 
to PE2 (3.2%- 5.5%; Fig. 1d). Again, the relative level of undesired indel formation was roughly 141 
proportional to the overall activity levels for PE2 and PE2*. We also observed that SaKKHPE2* 142 
could generate 18bp replacement with efficiencies ranging from 1.3% to 4.2% (Fig. 1d). Across 143 
all of these reporter systems, we observed that nicking the nonedited strand (PE3 format) 144 
increased the editing efficiency by 1.5- to 2.4-fold and the indel rate by 0.2 % to 3.3 % compared 145 
to pegRNA only in both PE2 and PE2* (Fig. 1b-d), consistent with previous observations6. 146 
Together, these results demonstrate that PE2* performed nucleotide conversion, sequence 147 
deletion or insertion more efficiently than PE2. In addition, the new SaCas9-based PEs displayed 148 
appreciable genome editing activity. 149 
 150 
Improved prime editor increases editing efficiency at endogenous loci 151 
Next, we compared the editing efficiency of PE2 and PE2* for the creation of previously described 152 
nucleotide substitutions, deletions and insertions at the EMX1 locus6. HEK293T cells were 153 
transfected with different prime editors, pegRNAs and different nicking sgRNAs. Genomic DNA 154 
was isolated and editing outcomes at each target site were quantified by high-throughput 155 
sequence (HTS). PE2* (3.1%- 6.5%) led to an average 1.9-fold increase in the rate of point 156 
mutation introduction compared to PE2 (1.5%- 3.7%) (Fig. 2a). Targeted 3bp deletions were 157 
generated at 1.4 to 2.1-fold higher rate by PE2* (2.1%- 6.0%) than PE2 (1.5%- 2.9%) (Fig. 2a). 158 
Targeted 6bp insertions were generated at 1.7 to 2.4-fold higher rate by PE2* (2.2%-3.1%) than 159 
PE2 (0.9%-1.8%) (Fig. 2a). As observed with the various reporter systems, the level of indel 160 
formation was roughly proportional to the activity levels of PE2 and PE2*. Together, these 161 
observations suggest that PE2* has broadly improved editing efficiency at endogenous loci. 162 
 163 
We also compared the editing efficiency of SaPE2* and SaKKHPE2* for the creation of similar 164 
nucleotide substitutions, deletions and insertions at the EMX1 locus. Notably, SaPE2* installed 165 
point mutations at two positions in the EMX1 locus with editing efficiency from 4.7% to 9.3% and 166 
a modest indel rate (0.0%-0.5%). Targeted 3-bp deletion and 6-bp insertion were introduced by 167 
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SaPE2* with an editing efficiency of 4.1% to 9.4% and 2.7% to 5.5%, respectively. Indel induction 168 
generated by SaPE2* ranged from 0.0% to 0.6% (Fig. 2b). Overall, SaKKHPE2* exhibited lower 169 
editing efficiency at the EMX1 locus than SaPE2* with the same set of pegRNAs (typically 170 
between 1 and 2%; Fig. 2c). Notably, at these loci the editing efficiencies for SaPE2* were similar 171 
to the rates obtained with PE2*, suggesting that the SaPE2* platform has the potential to broaden 172 
the scope of available prime editing systems. 173 
 174 
A homozygous 32-bp deletion in the CCR5 gene is associated with resistance to human 175 
immunodeficiency virus (HIV-1) infection24-26. We evaluated the utility of PE2 and PE2* to 176 
generate a large, therapeutically relevant 32-bp deletion within CCR5 that recapitulates the HIV-177 
1 resistance allele (Fig. 2d). We utilized linear amplification to incorporate unique molecular 178 
identifiers (UMI) prior to sequencing27 to avoid PCR amplification bias for the assessment of the 179 
deletion rate in the population of treated cells. Both PE2 and PE2* were able to generate the 180 
desired 32-bp deletion within the CCR5 locus in HeLa cells, where the PE2* editor displayed 181 
higher deletion rates than PE2 (average 1.4-fold across all conditions) with a maximum efficiency 182 
of about 6.0% (Fig. 2e, Supplementary Fig. S3). SaKKHPE2* exhibited lower editing efficiency 183 
than PE2 for the generation of the 32-bp deletion, with a maximum efficiency of 2.9% (Fig. 2e, 184 
Supplementary Fig. S3). Overall, these results demonstrate that PE can introduce a 185 
therapeutically relevant deletion in the CCR5 gene in human cells.  186 
 187 
Improved PE increases the correction efficiency of a pathogenic mutation in vivo 188 
 189 
Alpha-1 antitrypsin deficiency (AATD) is an inherited disorder that is caused by mutations in the 190 
Serpin Peptidase Inhibitor Family A member 1 (SERPINA1) gene28. The E342K mutation (via 191 
G•C-to-A•T) in SERPINA1 (PiZ allele) is the most frequent mutation and causes severe lung and 192 
liver disease28. Patients with homozygous mutation in SERPINA1 (PiZZ) have PiZ protein 193 
aggregates in hepatocytes and lack of functional AAT protein in the lung. The PiZ transgenic 194 
mouse contains 16 copies of the human SERPINA1 PiZ allele and is a commonly-used mouse 195 
model of human AATD 29. For the correction of the E342K mutation, there are some challenges 196 
for the utilization of an adenine base editor: no optimal NGG PAM is present nearby for SpCas9, 197 
and in addition to the target adenine there are several other adenines that may also be susceptible 198 
to base conversion (“bystander effect”)30. Consequently, we investigated the utilization of the PE 199 
platform to correct this pathogenic mutation. To test the efficiency of different prime editors at this 200 
locus, we first evaluated the generation of the pathogenic E342K mutation (via G•C-to-A•T 201 
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conversion) in wildtype SERPINA1 in HEK293T cells. A series of different nicking sgRNAs were 202 
also evaluated in conjunction with the PEs (PE3 strategy6). We observed 1.6 to 3.4-fold increase 203 
for G•C-to-A•T base transition in SERPINA1 by PE2* (6.4%-15.8%) compared to PE2 (1.9%-204 
9.9%; Fig. 3a). The average rate of indel generation with a nicking sgRNA slightly increased with 205 
PE2* (0.1% -3.8%) compared to PE2 (0.0%-2.2%). SaKKHPE2* exhibited lower overall editing 206 
efficiency for the installation of the E342K mutation (1.1%-4.4%). Indel generation at the target 207 
site by SaKKHPE2* ranged from 0.0% to 1.4% (Fig. 3a).  208 
 209 
Next, we investigated the ability of prime editors to directly correct a pathogenic mutation in vivo. 210 
Based on the editing results for SERPINA1 in HEK293T cells, we chose the nicking sgRNA3 for 211 
use with the PEs for the in vivo experiments. We utilized a different pegRNA designed to revert 212 
the E342K mutation (Fig. 3b). A PAM mutation (AGG to AAG) was also included to reduce re-213 
cutting of the locus that introduced a synonymous codon change (Fig. 3b). We introduced PE2 214 
or PE2*, pegRNA and nicking sgRNA into the liver of PiZ mice (n=3/group) through hydrodynamic 215 
tail vein injection (Fig. 3c). Hydrodynamic injection can deliver plasmid DNA to 20-30% of 216 
hepatocytes 31. Using a PE2 plasmid encoding an HA-tag, we observed that 19.98 ± 0.88% 217 
hepatocytes were HA-tag positive (n=4 mice) (Supplementary Fig. 4a). 45 days after injection, 218 
livers of PiZ mice were collected and DNA was purified for HTS analysis. Notably, we observed 219 
3.1-fold increase for A•T-to-G•C correction in PiZ SERPINA1 by PE2* (6.7% on average) 220 
compared to PE2 (2.1%). The indel rate at the locus was also increased from 0.4% to 2.7% (Fig. 221 
3d). Interestingly, we observed a low frequency of large deletions between pegRNA and nicking 222 
sgRNA (Supplementary Fig. S4b). Together, these data demonstrate that prime editors can 223 
restore the wild type SERPINA1 allele thereby enabling pathogenic gene correction in adult mice. 224 
 225 
Improved PE enhances tumor burden by somatic engineering in the mouse liver 226 
 227 
CTNNB1 (β-catenin) is a commonly mutated gene in hepatocellular carcinoma32. Overexpression 228 
of a mutant Ctnnb1 and Myc oncogene have been used to generate liver cancer models14. To 229 
explore the potential of prime editors to drive tumor formation in vivo, we delivered PE2 or PE2*, 230 
a pegRNA used for installation (via C•G-to-T•A) of the oncogenic S45F mutation in Ctnnb1 (Fig. 231 
4a), and a nicking sgRNA to the livers of adult FVB mice (n=4/group) by hydrodynamic tail vein 232 
injection (Fig. 4b). A MYC transposon and transposase were co-injected to provide a second 233 
oncogenic driver necessary for tumor formation in conjunction with the Ctnnb1 mutation33. 25 234 
days after injection, livers of adult mice were collected and tumor nodules on the liver were 235 
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quantified. PE2-treated animals showed an average 5.5 ± 1.1 tumors per mouse, whereas PE2*-236 
treated mice displayed higher rates of tumor formation, with an average 10.0 ± 2.7 tumors on the 237 
liver (Fig. 4c,d). Consistent with gain of function of the S45F mutation, liver tumors were positive 238 
for nuclear β-Catenin14 (Supplementary Fig.5). Sanger sequence of gDNA from the tumor 239 
nodules showed precise conversion of S45F in Ctnnb1 (Fig. 4e).  240 
 241 
Prime editors afford the opportunity to install other types of mutations within the genome. To 242 
assess the feasibility of generating deletions in vivo, we designed a pegRNA to delete the S45 243 
codon in Ctnnb1, which is a previously described oncogenic mutation at this locus 34(Fig. 4f). The 244 
prime editor (PE2*), pegRNA for Ctnnb1 S45 deletion and nicking sgRNA plasmids were delivered 245 
by hydrodynamic tail-vein injection along with the MYC transposon and transposase plasmids. 246 
pegRNA Ctnnb1 S45 deletion-treated animals showed extensive tumor formation, whereas 247 
pegRNA SERPINA1-treated animals did not induce any tumor formation (Fig. 4g). Deep 248 
sequencing showed that more than 80% of tumor gDNA contained precise editing removing the 249 
S45 codon (Fig. 4h). Together, these results demonstrate that prime editors can be used for 250 
generating tumor models by somatic cell engineering in vivo, and that PE2* provides a platform 251 
with improved editing activity.  252 
 253 
Utilizing a split-intein approach for prime editor delivery 254 
 255 
The ~6.3-kb coding sequence of PE exceeds the ~4.8-kb packaging size limit of AAV35. To deliver 256 
prime editors with AAVs, we adapted a split Cas9 dual-AAV strategy36 in which the original PE2 257 
prime editor is divided into an amino-terminal (PE2-N) and carboxy-terminal (PE2-C) segments, 258 
which are then reconstituted to full length PE by a trans-splicing intein37 (Fig. 5a). To ensure that 259 
each prime editor segment is smaller than the AAV packaging size limit, we divided the PE within 260 
the SpCas9 amino acid before Ser 71438. We generated AAV8 particles encoding the split-intein 261 
PE, a nicking sgRNA and a pegRNA (PE3 strategy6) to correct the E342K mutation in SERPINA1 262 
(Fig. 5a). We then characterized the performance of the split-intein AAV prime editor in vivo. PiZ 263 
mice were treated by tail-vein injection of a low dose dual AAV8-PE (2 × 1011 viral genome total) 264 
(Fig. 5b). Livers were harvested at 2 weeks (n=2), 6 weeks (n=3) and 10 weeks (n=3) after 265 
injection. By targeted deep sequencing, we detected 0.6 ± 0.0 % precise editing at 2 weeks. The 266 
precise editing efficiency increased significantly to 2.3 ± 0.4 % at 6 weeks and 3.1 ± 0.6 % at 10 267 
weeks (Fig. 5c). We observed corresponding increases of indel rates at the target site by split-268 
intein AAVs from 0.1 ± 0.0 % (2 weeks) to 0.4 ± 0.1 % (10 weeks). Utilization of the UDiTaS 269 
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unidirectional sequencing approach39 with locus specific primers for library construction affords 270 
the opportunity to assess the rate of large deletions or other types of genomic rearrangements in 271 
an unbiased manner. UDiTaS analysis at the SERPINA1 transgene locus revealed primarily 272 
precise editing among the modified alleles. As observed by the amplicon deep sequencing, a 273 
fraction of the modified alleles contained indels and there were a small number of larger deletions 274 
between the two nicking sites or extending beyond these sites, although many of the largest 275 
deletions (>100 bp) did not meet the level of statistical significance (Fig. 5d-e, Supplementary 276 
Fig. 6 and Supplementary table 5). There was also evidence of a very low rate of AAV insertion 277 
at the target site (0.014% of total UMIs). Together, these results demonstrate that delivery of split-278 
intein PE by the dual AAV8 enables low rates of precise editing via the PE3 prime editing strategy 279 
in vivo.  280 
 281 
Discussion 282 
Prime editing systems potentially provide a powerful approach for the template-directed 283 
incorporation of a variety of types of alterations (nucleotide changes, insertions, deletions) into 284 
genomic DNA sequence without relying on homology directed repair 6. In principle, this provides 285 
a strategy for the correction of a variety of different disorders, since prime editing should not be 286 
dependent on the cell cycle for efficacy as is HDR2. Moreover, unlike HDR and MMEJ40 287 
approaches for precise sequence insertions, prime editing does not require co-delivery of donor 288 
DNA. However, the length of the sequence that can be inserted is limited by the length of the 289 
encoded pegRNA. While there are many potential advantages to prime editing, the development 290 
of prime editing systems is in its initial stages, and many questions with regard to the utility of this 291 
system for genome editing remain to be addressed. This study provides an important 292 
demonstration of the in vivo utility of prime editors for the template-based modification of genomic 293 
sequence with implications for improving the utility of disease model systems and for the eventual 294 
translation of this tool to the correction of pathogenic disorders.   295 
 296 
The efficacy of genome editing systems is dependent on a number of factors, one of which is the 297 
efficiency of nuclear import. In rapidly proliferating cells, the nuclear envelope provides only a 298 
modest barrier to entry for genome editing tools. However, in post-mitotic or quiescent cells the 299 
nuclear envelope may provide a greater barrier to the entry of Cas9-based systems, such that the 300 
number and composition of the NLS sequences can impact editing efficacy 3, 12-16. By incorporating 301 
additional NLSs, we developed an improved PE (PE2*) that increases the efficiency of genome 302 
editing across multiple endogenous sites relative to the original PE2. Importantly, the observed 303 
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improvements in genome editing for PE2* in cell culture translated to increased rates of genome 304 
editing in vivo. Thus, demonstrating that NLS sequence composition and architecture is an 305 
important parameter to consider in the design of prime editing systems to maximize in vivo efficacy, 306 
as has been observed for other genome editing systems 3, 36. 307 
 308 
This study provides an important proof-of-concept demonstration of the feasibility of in vivo editing 309 
of somatic cells in mammalian systems by prime editing. We demonstrated the utility of prime 310 
editing systems for two different types of applications: the correction of a pathogenic mutation 311 
(AATD) and generation of animal cancer model. The ability to precisely correct a pathogenic 312 
mutation or install somatic mutations in vivo has important implications for both gene therapy and 313 
the development of new mouse models to study cancer and other disorders41. Using 314 
hydrodynamic injection, PE2* shows higher editing efficiency (~6%, Fig. 3) than previously 315 
published HDR (~0.5%)42 in the mouse liver for installing oncogenic point mutations. Future work 316 
will address whether PEs can simultaneously generate cooperating oncogenic point mutations (a 317 
list of potential mutations that can be studied is in Supplementary Table 4).  318 
 319 
Compared with HDR and base editors, prime editing provides a complementary method for 320 
generating precise genome alterations. Although a PE is less efficient than base editors for 321 
introducing base transitions, a PE can generate precise nucleotide substitutions in target sites 322 
where the neighboring sequence composition could potentially be challenging for precise 323 
conversion by base editing systems 6. Both of our in vivo target sites have neighboring nucleotides 324 
that would potentially be susceptible to conversion when targeted by a base editor (bystander 325 
effects). In the case of the SERPINA1 locus, these bystander changes would introduce missense 326 
mutations that could have undesirable effects.  327 
 328 
Prime editing systems can also produce undesired editing outcomes in some instances11. The 329 
use of the PE2 system in cell culture systems produces primarily precise edits6. The rate of precise 330 
edits can be increased through the use of an additional nicking sgRNA (PE3 strategy), but this 331 
also results in the production of a low rate of indels within the genome6, 11. Prime editing in plant 332 
protoplasts also produces a fraction of undesired editing outcomes when employing either the 333 
PE2 and PE3 strategy7. Interestingly, in mouse zygotes the PE3 strategy produces alleles 334 
containing the desired edit, but a large fraction also harbor deletions of various sizes between the 335 
target site and the nicking site 11. Reassuringly, for our in vivo PE3 editing the majority of modified 336 
alleles contain the intended product without additional modifications. Similar to the observation in 337 
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted December 16, 2020. ; https://doi.org/10.1101/2020.12.15.422970doi: bioRxiv preprint 
11 
 
cell culture experiments, we observe a small fraction of the alleles that contain unintended 338 
changes (indels). A small proportion of these (~6.6% modified alleles) contain deletions between 339 
the pegRNA and nicking sgRNA sites. Employing a sequential nicking strategy (PE3b) approach 340 
instead of PE3 may reduce the indel rates in vivo, as observed in other systems6, 7, when an 341 
overlapping nicking RNA can be designed at the prime editor target site.  342 
 343 
We established a dual-AAV system to deliver split-intein prime editors that produces precise 344 
editing in vivo following a single injection. While we focused on liver editing, the dual AAV-345 
mediated prime editor developed in this study should be applicable to other organ systems. 346 
Because AATD requires a high level of gene correction to generate sufficient wildtype protein for 347 
disease amelioration28, our initial AAV PE design is suboptimal for AATD treatment. Future work 348 
will be required to increase PE efficiency in vivo. The modest editing efficiency of our AAV system 349 
may be due in part to the low vector dose (2x1011 vg/kg total). In addition, some aspects of our 350 
design of split-PE AAV vectors could be improved. We retained the original PE2 architecture in 351 
our split-intein design due to its more compact size for vector packaging – substitution of the SV40 352 
NLSs with more efficient bipartite SV403 or c-myc NLSs17 may improve in vivo activity. Optimizing 353 
the position of intein insertion within the PE may also improve activity, as may alteration of the 354 
AAV vector layout and promoters that are utilized 36. The more compact SaPE2* or SaKKHPE2* 355 
systems described herein may also have utility in the context of AAV delivery once they are further 356 
optimized. In addition, the development of nanoparticle-mediated delivery or direct RNP delivery 357 
could also provide alternate avenues for translation of this tool for in vivo therapeutic application 358 
without the constraints of AAV cargo capacity. Once the efficiency of prime editing systems in 359 
vivo is improved, it will also be important to explore in greater depth the frequency of off-target 360 
editing before these systems are transitioned to gene therapy applications. In summary, our 361 
findings demonstrate the broad potential scope of PEs for in vivo genome editing, both for disease 362 
gene correction and the development of new cancer models in adult animals. 363 
 364 
Methods 365 
Generation of plasmids  366 
To generate pegRNA expression plasmids, PCR products including spacer sequences, scaffold 367 
sequences and 3’ extension sequences were amplified with indicated primers (Supplementary 368 
table 2) using Phusion master mix (ThermoFisher Scientifc) or Q5 High-Fidelity enzyme 369 
(NewEnglandBioLabs), which were subsequently cloned into a custom vector (Supplementary 370 
sequence 2, BfuAI and EcoR I digested) by the Gibson assembly method (NEB). To generate 371 
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nicking sgRNA expression plasmids, annealed oligos were cloned into BfuAI-digested vector or 372 
pmd264 vector (Supplementary sequence 2). Sequences of all pegRNA and nicking sgRNAs are 373 
listed in Supplementary Table 1. PE2* was generated through Gibson assembly, by combining 374 
SpyCas9(H840A) and the M-MLV RT from PE2 6 with additional NLS sequences by PCR and 375 
inserting into a NotI/PmeI-digested pCMV-PE2  backbone (Supplementary sequence 3). SaPE2* 376 
and SaKKHPE2* were generated through Gibson assembly, by combining the following three DNA 377 
fragments: (i) PCR amplified M-MLV RT with additional NLS sequences from PE2, (ii) a 378 
NotI/PmeI-digested PE2 backbone, (iii) a SaCas9 N580A nickase or a SaKKH-Cas9 nickase 379 
(supplementary sequence 3). All plasmids used for in vitro experiments were purified using 380 
Midiprep kit including endotoxin removal step (Qiagen).  pCMV-PE2 was a gift from David Liu 381 
(Addgene plasmid # 132775) 6. AAV-PE-N was generated through Gibson assembly, by 382 
combining the following five DNA fragments: (i) gBlock pegRNA driven by U6, (ii) gBlock nicking 383 
sgRNA driven by U6, (iii) PCR amplified N-terminal PE2 (amino acid 1-713 of SpCas9 H840A), 384 
(iv) gBlock split-intein N terminal, (v) a KpnI/SacI-digested AAV backbone43. AAV-PE-C was 385 
generated through Gibson assembly, by combining the following four DNA fragments: (i) gBlock 386 
split-intein C terminal, (ii) PCR amplified C-terminal PE2 (amino acid 714-1368 of SpCas9 H840A) 387 
and M-MLV RT from PE2, (iii) gBlock β-globin poly(A) signal, (iv) a KpnI/NotI-digested AAV 388 
backbone.   389 
 390 
AAV vector production 391 
 392 
AAV vectors (AAV8 capsids) were packaged at the Viral Vector Core of the Horae Gene Therapy 393 
Center at the University of Massachusetts Medical School. Vector titers were determined by gel 394 
electrophoresis followed by silver staining and qPCR. 395 
 396 
Generation reporter cells and Cell culture conditions 397 
HEK293T cells were purchased from ATCC, and cells were maintained in Dulbecco’s Modified 398 
Eagle’s Medium supplemented with 10% FBS. For generation of the mCherry reporter and 47bp-399 
insertion TLR reporter cells, we created single-copy reporter cells using the Invitrogen Flp-In 400 
system. Briefly, Flp-In 293T cells were maintained in DMEM, 10% Fetal bovine serum (FBS), 1% 401 
pen-strep and 100 μg/ml Zeocin. 1x106 Flp-In 293T cells were plated in a 6 well plate 24 hours 402 
before transfection. On the day of transfection, the cells were washed and fresh media without 403 
Zeocin was added. The plasmid coding for FLP recombinase and the mCherry reporter or 47bp-404 
insertion TLR reporter plasmid were transfected into the cells at a 9:1 ratio using polyfect 405 
(QIAGEN) according to the manufacturer’s protocol (900ng mCherry reporter or 47bp-insertion 406 
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TLR reporter plasmid and 100ng FLP recombinase plasmid to make 1 μg plasmid in total). 48 407 
hours following transfection, the cells were washed and split into a 10cm dish with fresh media. 408 
100 μg/ml of hygromycin was used to select for cells that contained an integration of the reporter 409 
plasmid. Two weeks post selection, hygromycin resistant foci were pooled and propagated for 410 
cryopreservation and further experiments. The construction an characterization of the TLR-MCV1 411 
reporter cells was described in 23. All cell types were maintained at 37°C and 5% CO2 and were 412 
tested negative for mycoplasma.  413 
 414 
Cell culture transfection/electroporation and DNA preparation 415 
For transfection-based editing experiments in HEK293T cells or HEK293T reporter cells, cells 416 
were plated 100,000 per well on a 48-well plate. 24 hours later, the cells were co-transfected with 417 
540ng of prime editor plasmid, 270ng of pegRNA plasmid and 90ng of Nicking sgRNA plasmid. 418 
Lipofectamine 2000 (Invitrogen) was used for the transfection according to the manufacturer’s 419 
instructions. FACS analysis was performed 3 days after transfection in HEK293T reporter cells. 420 
To detect editing efficiency in endogenous genomic loci, HEK293T cells were cultured for 3 days 421 
after transfection, and genomic DNA was isolated using QIAamp DNA mini kit (QIAGEN) 422 
according to the manufacturer’s instructions. For CCR5 PE editing, the same amount of plasmid 423 
were delivered (540ng of prime editor plasmid, 270ng of pegRNA plasmid and 90ng of Nicking 424 
sgRNA plasmid), where 2 × 105 HeLa cells were treated per electroporation using the Neon® 425 
TransfectionSystem 10 L Kit (Thermo Fisher Scientific) with the recommended electroporation 426 
parameters: Pulse voltage (1350 v), Pulse width (10 ms), Pulse number (3).  427 
 428 
Fluorescent reporter assay 429 
48 h post-transfection cells are trypsinized and harvested into a microcentrifuge tube. Cells are 430 
centrifuged at 500×g for 2 min, washed once with 1× PBS, recentrifuged at 500×g for 2 min and 431 
resuspended in 1× PBS for flow cytometry (Becton Dickonson FACScan). 10,000 events were 432 
counted from each sample for FACS analysis. Experiments were performed in six replicates on 433 
different days. The data are reported as mean values with error bars indicating SD. 434 
 435 
Immunofluorescence and  immunohistochemistry 436 
HeLa and U2OS cells are transfected in six-well format via Lipofectamine 2000 (Invitrogen) using 437 
the manufacturer’s suggested protocol with 300 ng each PE expression plasmid and 150 ng of 438 
each pegRNA expression plasmid on a cover slip. 48 h following transfection, transfection media 439 
was removed, cells were washed with 1× PBS and fixed with 4% formaldehyde in 1× PBS for 15 440 
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min at room temperature. Following blocking (blocking solution: 2% BSA, 0.3% Triton X-100, 441 
within 1× PBS), samples were stained with mouse antihemagglutinin (Sigma, H9658, 1:500), and 442 
Alexa 488 donkey anti-mouse IgG (H+L; Invitrogen, A-21202, 1:2000), sequentially. 443 
VECTASHIELD mounting medium with DAPI (Vector Laboratories, H-1200) was used to stain the 444 
nuclei and to mount the samples on the slide. Images were taken with ZEISS LSM 710 Confocal 445 
Microscope System. We used Fiji44 and the “CMCI-EMBL” plugin to calculate the signal from the 446 
nuclear or cytoplasm comparments as previously described45 447 
(https://github.com/miura/NucleusRimIntensityMeasurementsV2/). We used 60 to 80 cells for 448 
each treatment group to determine the nuclear to cytoplasmic ratio for each PE construct, which  449 
was calculated as the intensity value from nucleus divided by the intensity value from cytoplasm 450 
and nucleus. 451 
IHC staining was performed as previously described42 using beta-catenin antibody (BD, 610154, 452 
1:100) or HA tag (CST, 3724, 1:400). 453 
 454 
Animal studies 455 
All animal experiments were authorized by the Institutional Animal Care and Use Committee 456 
(IACUC) at UMASS medical school. No animals were excluded from the analyses. All prime editor 457 
plasmids were prepared by EndoFreeMaxi kit (Qiagen) and were delivered through hydrodynamic 458 
tail-vein injection. For PiZ correction, eight-week-old PiZ mice were injected with 2.3ml 0.9% 459 
saline containing 30μg PE2 or PE2* (n=3), 15μg pegRNA (SERPINA1) and 5μg Nicking sgRNA 460 
3. For cancer model generation, FVB/NJ (Strain #001800) was purchased from Jackson 461 
Laboratories. Each FVB mouse (n=4) was injected with 2.3ml 0.9% saline containing 30μg PE2 462 
or PE2*, 15μg pegRNA (Ctnnb1), 15μg Nicking sgRNA 2 (Ctnnb1), 5μg pT3 EF1a-MYC (a gift 463 
from Xin Chen, Addgene plasmid # 92046)33 and 1μg CMV-SB10 (a gift from Perry Hackett, 464 
Addgene plasmid # 24551).  465 
 466 
Deep sequencing and data analysis 467 
Library construction for deep sequencing is modified from our previous report27. Briefly, 72 h after 468 
transfection or electroporation, cells were harvested and genomic DNA was extracted with 469 
GenElute Mammalian Genomic DNA Miniprep Kit (Sigma). Genomic loci spanning the target and 470 
off-target sites were PCR amplified with locus-specific primers carrying tails complementary to 471 
the Truseq adapters (Supplementary Data 3). 50 ng input genomic DNA was PCR amplified with 472 
Q5 High-Fidelity DNA Polymerase (New England Biolabs): (98 °C, 15 s; 67 °C 25 s; 72 °C 20 s) 473 
×30 cycles. For the construction of the CCR5 UMI-based library, 50 ng input genomic DNA was 474 
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first linearly pre-amplified with 10 nM final concentration 5p-CCR5_UMI primer using the Q5 High-475 
Fidelity DNA Polymerase (New England Biolabs): (98 °C, 60 s; 67 °C, 25 s; 72 °C, 20 s) × 10 476 
cycles. In the same reaction mix, 500 nM final concentration 5p-DS_constant and 3p-CCR5_DS 477 
primers were added for further amplification (98 °C, 60 s; 67 °C, 25 s; 72 °C, 20 s) for 30 cycles. 478 
Next, 0.1 μl of each PCR reaction was amplified with index-containing primers to reconstitute the 479 
TruSeq adaptors using the Q5 High-Fidelity DNA Polymerase (New England Biolabs): (98 °C, 15 480 
s; 67 °C, 25 s; 72 °C, 20 s) x10 cycles. Equal amounts of the PCR products from each 481 
experimental condition (identified by different indices) were pooled and gel purified. The purified 482 
library was deep sequenced using a paired-end 150 bp Illumina MiniSeq run.  483 
 484 
MiniSeq data analysis was done as previously reported 27. First, the quality of paired-end 485 
sequencing reads (R1 and R2 fastq files) was assessed using FastQC 486 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Raw paired-end reads were 487 
combined using paired end read merger (PEAR) (PMID: 24142950) to generate single merged 488 
high-quality full-length reads. Reads were then filtered by quality (using Filter FASTQC (PMID: 489 
20562416)) to remove those with a mean PHRED quality score under 30 and a minimum per 490 
base score under 24. Each group of reads was then aligned to a corresponding reference 491 
sequence using BWA (version 0.7.5) and SAMtools (version 0.1.19). To determine indel 492 
frequency, size and distribution, all edited reads from each experimental replicate were combined 493 
and aligned, as described above. Indel types and frequencies were then cataloged in a text output 494 
format at each base using bam-readcount (https://github.com/genome/bam-readcount). For each 495 
treatment group, the average background indel frequencies (based on indel type, position and 496 
frequency) of the triplicate negative control group were subtracted to obtain the precise editing 497 
and indel frequencies for each group. The fraction of precise editing is calculated as sequencing 498 
reads with the desired allele editing/ all reads for the target locus. The results were concatenated 499 
and loaded into GraphPad Prism 8.4 for data visualization.  500 
 501 
Tn5 tagmentation and library preparation for UDiTaS 502 
 503 
For tagmentation, transposome was assembled as previously described39 using purified Tn5 504 
protein and oligonucleotides purchased from IDT. 200ng of genomic DNA was incubated with 2ul 505 
of assembled transposome at 55 degree for 7 mins, and the product was cleaned up (20ul) with 506 
a Zymo column (Zymo Research, #D4013). Tagmented DNA was used for the 1st PCR using 507 
PlatinumTM SuperFi DNA polymerase (Thermo) with i5 primer and gene specific primers 508 
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(Supplementary table 3). Two different libraries were prepared for gDNA from each mouse with 509 
different combinations of primers (i5+Locus_F [UDiTaS], i5+Locus_R [UDiTaS]). The i7 index was 510 
added in the 2nd PCR and the PCR product was cleaned up with Ampure XP SPRI beads 511 
(Agencourt, 0.9X reaction volume). Completed libraries were quantified by Tapestation and Qubit 512 
(Agilent), pooled with equal mole and sequenced with 150 bp paired-end reads on an Illumina 513 
MiniSeq instrument.  514 
 515 
UDiTaS data analysis 516 
The analysis pipeline was built using python code. Briefly, the analysis steps are as follows: 517 
i) Demultiplexing. Raw BCL files were converted and demultiplexed using the appropriate 518 
sequencing barcodes, allowing up to one mismatch in each barcode. Unique molecular 519 
identifiers (UMIs) for each read were extracted for further downstream analysis. 520 
ii) Trimming. Remove 3 adapters using cutadapt, version 3.0  521 
http://journal.embnet.org/index.php/embnetjournal/article/view/200/479 522 
iii) Create reference sequence based the UDiTaS locus-specific primer position and AAV plasmid 523 
map separately. Build index files for the reference using bowtie2-index46, version 2.4.0. 524 
iv) Alignment analysis. Paired reads were then globally aligned (end-to-end mode) to all the 525 
reference amplicons using bowtie2’s very sensitive parameter. Finally, samtools47 (version 526 
0.1.19) was used to create and index sorted bam files. Paired-end reads covering a window 527 
between pegRNA targeting site and nicking sgRNA targeting sites were extracted and the 528 
total number of unique UMIs were counted. Precise editing or small indels were analyzed as 529 
previously described27. Pindel48 (version 0.2.5b8) was used to detect breakpoints of large 530 
deletions. Raw sequencing reads that align to the reference sequence were collapse to a 531 
single read by common UMI and categorized as an exemplar for each UMI to a specific 532 
category—for example, Wild Type, precise editing, small indel/substitution and Large 533 
Deletions. Then the number of UMIs assigned per category is determined to define the ratio 534 
of each event. 535 
v) AAV integration. Extract the unmapped reads that did not locally align to the AAV/plasmid in 536 
steps 3 and 4 using bedtools bamtofastq. With bowtie2, index the AAV plasmid sequence and 537 
then do a local alignment of the reads. Of the reads that locally align to the AAV plasmid, first 538 
filter out those reads which are directly adjacent to the UDiTaS primer (on read 2) and do not 539 
contain any target locus sequence. This removes reads that are due to false priming. Of the 540 
remaining reads, collapse these by UMI and count the UMIs. Classify the exemplar read for 541 
each UMI as ‘AAV/Plasmid Integrations’. 542 
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The software used for the above analysis is available at:  544 
https://github.com/locusliu/GUIDESeq-Preprocess_from_Demultiplexing_to_Analysis 545 
https://github.com/editasmedicine/uditas. https://github.com/ericdanner/REPlacE_Analysis. 546 
and https://github.com/locusliu/PCR_Amplicon_target_deep_seq/blob/master/CRESA-lpp.py. 547 
Statistical analysis  548 
The fold changes of editing (precise editing or indels) are calculated between the corresponding 549 
groups: pegRNA_only between PE2 and PE2*, or with specific Nicking sgRNA between PE2 and 550 
PE2*. All raw data is listed in Supplementary Table 6 and statistical analyses were performed 551 
using GraphPad Prism 8.4. Sample size was not pre-determined by statistical methods, but 552 
rather, based on preliminary data. Group allocation was performed randomly. In all studies, data 553 
represent biological replicates (n) and are depicted as mean ± s.d. as indicated in the figure 554 
legends. Comparison of mean values was conducted with one-way ANOVA with Tukey’s multiple 555 
comparisons test, as indicated in the figure legends. In all analyses, P values < 0.05 were 556 
considered statistically significant.  557 
 558 
Data availability 559 
Illumina Sequencing data have been submitted to the Sequence Read Archive. These datasets 560 
are available under BioProject Accession number PRJNA496245.The authors declare that all 561 
other data supporting the findings of this study are available within the paper and its 562 
Supplementary Information files or upon reasonable request. Backbone plasmids used for 563 
pegRNA and sgRNA cloning are available from addgene.  564 
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Figure Legends: 585 
Fig. 1 Improved NLS composition enhances prime editing efficiency. (a) Schematic 586 
representation of the original primer editor (PE2) and optimized prime editor (PE2*) carrying 587 
additional NLS sequences at the N-terminus and C-terminus. The M-MLV reverse transcriptase 588 
in PE2 was fused to a SaCas9 nickase (SaPE2*) or a SaCas9KKH nickase (SaKKHPE2*) with the 589 
same NLS composition to develop orthogonal prime editors. vBP-SV40 NLS = variant BP-SV40 590 
NLS. (b) Diagram of the A•T-to-G•C transition required to convert a stop codon to GLN to restore 591 
function to an mCherry reporter in HEK293T cells (top). Frequencies of targeted A•T-to-G•C 592 
transition by different prime editors (PE2, PE2* and SaKKHPE2*) were quantified by flow cytometry 593 
(bottom). (c) Diagram of the deletion reporter in HEK293T cells containing a broken GFP with 47-594 
bp insertion, P2A, and out-of-frame mCherry (top). A targeted, precise deletion of 47bp will restore 595 
GFP expression, whereas indels that create a particular reading frame alteration produce 596 
mCherry expression. Frequencies of precise deletion (GFP+) and indel (mCherry+) introduced by 597 
different prime editors (PE2, PE2*, and SaKKHPE2*) were quantified by flow cytometry (bottom). 598 
(d) Diagram of the insertion reporter in HEK293 cells containing a broken GFP with 39-bp insertion, 599 
T2A and mCherry (top). A targeted, precise insertion of 18bp that substitutes for a disrupting 600 
sequence can restore GFP expression, whereas indels that create a particular reading frame 601 
alteration produce mCherry expression. Frequencies of targeted 18-bp replacement and indel 602 
generation by different prime editors (PE2, PE2*, and SaKKHPE2*) were quantified by flow 603 
cytometry (bottom). All expression vectors were delivered by transient transfection. The presence 604 
of sgRNAs to promote nicking of the complementary strand is indicated in each figure legend. 605 
Results were obtained from six independent experiments and presented as mean ± SD. **P<0.01, 606 
***P<0.001, ****P<0.0001 by one-way ANOVA with Tukey’s multiple comparisons test between 607 
each PE2 and PE2* using the same nicking sgRNA.  608 
 609 
Fig. 2 Improved PE2* increases editing efficiency at endogenous loci. (a) Comparison of 610 
editing efficiency for nucleotide substitution, targeted 3-bp deletion, and 6-bp insertion with PE2 611 
and PE2* at EMX1 locus in HEK293T cells. Indels broadly indicates mutations to the endogenous 612 
sequence that do not result in the desired sequence alteration. (b-c) Editing efficiency for 613 
nucleotide substitution, targeted 3-bp deletion, and 6-bp insertion with SaPE2* (b) and SaKKHPE2* 614 
(c) at EMX1 locus in HEK293T cells. (d) Sequence of CCR5 locus and pegRNA used for the 32bp 615 
deletion. Two mutations in red were included to demonstrate that sequence collapse was not a 616 
function of nuclease-induced microhomology mediated deletion and to reduce re-cutting of 617 
deletion allele. Bottom panel shows the alignment of pegRNA with the CCR5 sense strand. (e) 618 
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted December 16, 2020. ; https://doi.org/10.1101/2020.12.15.422970doi: bioRxiv preprint 
20 
 
Comparison of efficiency for generating a targeted 32-bp deletion with PE2, PE2*, and SaKKHPE2* 619 
within CCR5 in HeLa cells. All expression vectors were delivered by transient transfection. The 620 
presence of sgRNAs to promote nicking of the complementary strand is indicated in each figure 621 
panel. Results were obtained from three independent experiments and presented as mean ± SD. 622 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by one-way ANOVA with Tukey’s multiple 623 
comparisons test. ns, not significant. 624 
 625 
Fig. 3 Improved PE2* increases the correction efficiency of a pathogenic mutation in vivo. 626 
(a) Installation (via G•C-to-A•T) of the pathogenic SERPINA1 E342K mutation in HEK293T cells 627 
using PE2, PE2*, and SaKKHPE2*. Editing efficiencies reflect sequencing reads which contain the 628 
desired edit. The presence of sgRNAs to promote nicking of the complementary strand is 629 
indicated on the x-axis. Results were obtained from three independent experiments and are 630 
presented as mean ± SD. (b) pegRNA used for correction (via A•T-to-G•C) of the E342K mutation 631 
includes a spacer sequence, a sgRNA scaffold, a RT template including edited bases (red) and 632 
a primer-binding site (PBS). A PAM mutation (AGG to AAG) was introduced to reduce re-cutting 633 
of the locus that results in a synonymous codon change. (c) Schematic overview of correction 634 
strategy of the SERPINA1 E342K mutation in PiZ transgenic mouse model of AATD. Prime editor, 635 
pegRNA and nicking sgRNA plasmid were delivered by hydrodynamic tail-vein injection. (d) 636 
Comparison of the efficiency of K342E correction and indels in mouse livers in PE2 or PE2* 637 
treatment groups. Precise editing is defined as the fraction of sequencing reads with both A to G 638 
prime editing and synonymous PAM modification. Results were obtained from three mice and 639 
presented as mean ± SD. **P<0.01, ***P<0.001, ****P<0.0001 by one-way ANOVA with Tukey’s 640 
multiple comparisons test.  641 
 642 
Fig. 4 Generating mouse cancer models using improved PE2*. (a) pegRNA used for 643 
installation (via C•G-to-T•A) of the oncogenic S45F in Ctnnb1 in mouse liver. (b) Schematic 644 
overview of the somatic cell editing strategy to drive tumor formation. Prime editor (PE2 or PE2*), 645 
pegRNA for Ctnnb1 S45F and nicking sgRNA plasmids were delivered by hydrodynamic tail-vein 646 
injection along with the MYC transposon and transposase plasmids. (c) Representative images 647 
of tumor burden in mouse liver with PE2 or PE2*. (d) Tumor numbers in the livers of mice 25 days 648 
after injection with PE2 or PE2*. Control group was pegRNA only. (e) Sanger sequencing from 649 
normal liver and representative tumors. The dashed box denotes C to T editing in tumors.  650 
*P<0.05 by one-way ANOVA with Tukey’s multiple comparisons test. (f) Schematic of Ctnnb1 S45 651 
deletion strategy using PE2* (S45del). pegRNA used for 3bp deletion (TCC) is shown. (g) PE2* 652 
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treatment leads to oncogenic activation of Ctnnb1. Prime editor (PE2*), pegRNA (Ctnnb1 S45del 653 
or SERPINA1) and nicking sgRNA plasmids were delivered by hydrodynamic tail-vein injection 654 
along with the MYC transposon and transposase plasmids. Mice treated with the pegCtnnb1 655 
S45del (n=4) displayed a large number of liver tumors whereas mice treated with pegSERPINA1 656 
as a control displayed no noticeable oncogenic lesions. beta-Catenin (CTNNB1) IHC staining was 657 
performed. Scale bars: 100 µm (20X lens). (h) Prime editing efficiency and indels determined by 658 
targeted deep sequencing in control liver and representative tumors.  659 
Fig. 5 Systemic injection of dual AAV8 split-intein prime editor achieves pathogenic 660 
mutation correction in PiZ mice. (a) Schematic of split-intein dual AAV prime editor. Full-length 661 
primer editor (original PE26) was reconstituted from two PE2 fragments employing the Npu DNAE 662 
split intein37. C, carboxy terminal; N, amino terminal. (b) Schematic of the in vivo dual AAV8 prime 663 
editor injection experiments. Dual AAV8 split-intein prime editor (2 × 1011 vg total) was delivered 664 
to six-week-old PiZ mice by tail-vein injection. Livers were harvested at 2 (n=2), 4 (n=3) and 10 665 
(n=3) weeks after injection and the genomic DNA was isolated for sequencing. (c) Prime editing 666 
efficiency of K342E correction and indels determined by targeted deep sequencing in mouse 667 
livers of dual AAV-treated mice. Precise editing is defined as the fraction of sequencing reads 668 
with both A to G prime editing and synonymous PAM modification. Results were obtained from 669 
two (2 weeks) or three mice (6 and 10 weeks) and presented as mean ± SD. **P<0.01, ***P<0.001 670 
by one-way ANOVA with Tukey’s multiple comparisons test. (d) Composition of edited alleles at 671 
SERPINA1 by UDiTaS analysis. Circle plot shows the fraction of edits that are precise (intended 672 
base conversion), small indels (<50bp) or substitution, deletions between pegRNA and nicking 673 
sgRNA sites (<100bp), large deletions (>100bp), and AAV fragment insertion. Numbers are 674 
average of 3 mice in 10 week treated cohort. (e) The statistically significant large deletion 675 
sequences detected by UDiTaS in the 10 week treated cohort are displayed as bars spanning the 676 
sequence that is deleted (a representative liver of n=3 mice). Positions of the pegRNA and nicking 677 
sgRNA are indicated by dotted lines and the approximate positions of the locus-specific UDiTaS 678 
primers are indicated by arrows below the bar chart. The deletion size and number of UMIs 679 
associated with each deletion are indicated to the right of each bar.  680 
 681 
Supplementary Fig. 1 Optimized prime editor increases the degree of nuclear import. (a) 682 
Representative immunofluorescence images of prime editors transfected into U2OS cells 683 
immunostained with a HA tag antibody to visualize subcellular localization. PE2 contains two 684 
SV40 NLSs, whereas the PE2* variant include an extra N-terminal c-Myc NLS and a C-terminal 685 
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variant bipartite SV40 NLS (vBPSV40). DNA was stained with DAPI. Scale bar, 100μm. (b) The 686 
nuclear/cytoplasm ratio of different prime editors as determined by confocal microscopy. (c-d) 687 
Representative immunofluorescence images and quantification in HeLa cells. ***P<0.001 by one-688 
way ANOVA with Tukey’s multiple comparisons test.  689 
 690 
Supplementary Fig. 2 Prime editing in reporter cells by PE2 and PE2*. (a) Sequence of 691 
reporter locus and pegRNA used for repair (via A•T-to-G•C transition) of mCherry reporter in 692 
HEK293T cells. Bar above the cDNA indicates the stop codon with the target “t” for conversion 693 
indicated in red. Two additional silent mutations are included to discourage recutting of the 694 
repaired DNA sequence (b) Sequence of reporter and pegRNA used for generation of a 47bp 695 
deletion to restore function of the GFP reporter in HEK293T cells. The bars above the cDNA 696 
indicates three nucleotide blocks that correspond to codons in the GFP reporter. (c) Sequence of 697 
reporter and pegRNA used for replacement of a 18bp element to restore function of the GFP 698 
reporter. The bars above the cDNA indicates three nucleotide blocks that correspond to codons 699 
in the GFP reporter. (d) Representative images of HEK293T reporter cells transfected with control, 700 
ABEmax or PE2*. Scale bar, 400μm.  701 
 702 
Supplementary Fig.3 Sequencing analysis of the CCR5 prime editing by PE2, PE2*, or 703 
SaKKHPE2*.  704 
The percentage of most common sequences in PE2, PE2* and SaKKHPE2* transfected cells is 705 
shown on the right (representative of n=3, determined by Illumina sequencing). The PE target site 706 
is underlined. The PAM sequences are indicated in light blue for SpCas9 and green for SaCas9KKH. 707 
The box denotes the 32bp sequence deleted in CCR5delta32. Two “t” mutations in red were 708 
included in the PE2 and PE2* RT template (Fig. 2d) to demonstrate that sequence collapse was 709 
not a function of nuclease-induced microhomology mediated deletion and to reduce re-cutting of 710 
deletion allele.  Deleted bases are indicated by dashes and inserted bases are in blue.  711 
 712 
Supplementary Fig.4 Sequencing analysis of SERPINA1 editing in the liver of PiZ mouse. 713 
(a) Evaluating prime editor expression in mouse liver. Left panel: FVB mice were injected with 714 
30μg of control vector or PE2 plasmid with HA-tag. Livers were harvested at day 2 and IHC 715 
staining were performed with an HA-tag antibody. Representative IHC images are shown. Scale 716 
bars: 100 µm (20X lens). Right panel: Quantification of HA+ cells. Numbers are mean + sem (n=4 717 
mice).   718 
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(b) The percentage of most common sequences in the liver of PE2 and PE2*-treated mice is 719 
shown on the right (representative liver of n=3, determined by Illumina sequencing). The PE target 720 
site is underlined. The PAM sequences are in light blue. Nucleotide substitutions are labeled in 721 
red. Deleted bases are indicated by dashes. Inserted bases are shown in blue/lower case.  722 
 723 
Supplementary Fig.5 Liver tumors are positive for nuclear beta-Catenin. (a), Representative 724 
H&E and beta-catenin IHC staining in PE2 or PE2*-induced S45F tumors in Fig. 4. Scale bars: 725 
100 µm (20X lens).  726 
 727 
Supplementary Fig. 6 Sequencing analysis of the Ctnnb1 and SERPINA1 prime editing by 728 
PE2 or PE2*. 729 
(a), The percentage of most common sequences in the liver of dual AAV-treated PiZ mice 730 
determined by locus amplification is shown on the right (representative liver of n=3). A portion of 731 
the PE target site is underlined. The PAM sequences are in light blue. Nucleotide substitutions 732 
are labeled in red. Deleted bases are indicated by dashes. (b), Length distribution of precise 733 
editing and other indels at SERPINA1 (K342E correction) and Ctnnb1 target sites by UDiTaS. 734 
Also included are sequence modifications that may be associated with pegRNA scaffold 735 
insertions7. A representative liver is shown (n=3 mice). 736 
 737 
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Figure S3
a
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTTCCATACAGTCAGTATCAATTCTGGAAGAATTTCCAGACATTAAAGATAGTCATCTTGGGGCTGGTCC        WT           94.82%
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTTCCtTAtA--------------------------------TTAAAGATAGTCATCTTGGGGCTGGTCC        Precise      3.86%
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTTCCA--------------------------------GACATTAAAGATAGTCATCTTGGGGCTGGTCC        -32              0.17%
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTTCCtTAtA---------------------------------TAAAGATAGTCATCTTGGGGCTGGTCC        -33              0.06%
PE2
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTC------------------ATCAATTCTGGAAGAATTTCCAGACATTAAAGATAGTCATCTTGGGGCTGGTCC        -18              0.04%
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTTCCATACAGTCAGTATCAATTCTGGAAGAATTTCCAGAC---AAAGATAGTCATCTTGGGGCTGGTCC        -3                0.03%
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTTCCATACAGTCAGTATCAATTCTGGAAGAATTTCCAGACcATTAAAGATAGTCATCTTGGGGCTGGTCC       +1               0.01%
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTTCCtTAtAG--------------------------------TAAAGATAGTCATCTTGGGGCTGGTCC        -32              0.08%
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTTCCATACAGTCAGTATCAATTCTGGAAGAATTTCCAGACATTAAAGATAGTCATCTTGGGGCTGGTCC        WT           91.25%
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTTCCtTAtA--------------------------------TTAAAGATAGTCATCTTGGGGCTGGTCC        Precise      6.08%
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTTCCA--------------------------------GACATTAAAGATAGTCATCTTGGGGCTGGTCC        -32              0.25%
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTTCCtTAtA---------------------------------TAAAGATAGTCATCTTGGGGCTGGTCC        -33              0.06%
PE2*
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTC------------------ATCAATTCTGGAAGAATTTCCAGACATTAAAGATAGTCATCTTGGGGCTGGTCC        -18              0.06%
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTTCCATACAGTCAGTATCAATTCTGGAAGAATTTCCAGAC---AAAGATAGTCATCTTGGGGCTGGTCC        -3                0.04%
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTTCCATACAGTCAGTATCAATTCTGGAAGAATTTCCAGACcATTAAAGATAGTCATCTTGGGGCTGGTCC       +1               0.03%
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTTCCtTAtAG--------------------------------TAAAGATAGTCATCTTGGGGCTGGTCC        -32              0.14%
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTT-----------------------------------GACATTAAAGATAGTCATCTTGGGGCTGGTCC        -33              0.08%
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTT--------GTCAGTATCAATTCTGGAAGAATTTCCAGACATTAAAGATAGTCATCTTGGGGCTGGTCC        -8                0,03%
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTT-----------------------------------GACATTAAAGATAGTCATCTTGGGGCTGGTCC        -33              0.04%
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTTCCATACAGTCAGTATCAATTCTGGAAGAATTTCCAGACATTAAAGATAGTCATCTTGGGGCTGGTCC        WT           96.36%
SaKKHPE2*
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTTCCATACA--------------------------------TTAAAGATAGTCATCTTGGGGCTGGTCC        Precise      2.85%
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTTCCA--------------------------------GACATTAAAGATAGTCATCTTGGGGCTGGTCC        -32              0.06%
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTTCCATACAGTCAGTATCAATTCTGGAAGAATTTCCAGAC---AAAGATAGTCATCTTGGGGCTGGTCC        -3                0.02%
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTTCCATACAGTCAGTATCAATTCTGGAAGAATTTCCAGAC-----------TCATCTTGGGGCTGGTCC        -11              0.02%
CAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTTCCATACAGTCAGTATCAATTCTGGAAGAA-----------------TAGTCATCTTGGGGCTGGTCC        -17              0.01%
CCR5 Delta32 Deletion
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Figure S4
a
CTCTCCCCTCCAGGCCGTGCATAAGGCTGTGCTGACCATCGACAAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   WT           93.8%
CTCTCCCCTCCAGGCCGTGCATAAaGCTGTGCTGACCATCGACgAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   Precise    2.87%
CTCTCCCCTCCAGGCCGTGC------------TGACCATCGACAAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   -12            0.14%
CTCTCCCCTCCAGGCCGTGCATAAaGCTGTGCTGACCATCGACgAGA--------------------GCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   -20            0.05%
PE2
CTCTCCCCTCCAGG-------------------------------------GACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   -37            0.05%
CTCTCCCCTCCAGGCCGTG----------TGCTGACCATCGACAAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   -10            0.03%
CTCTCCCCTCCAGGCCGTGC--------------------------------------------------------------------------------CCCCCCGA   -80            0.03%
CTCTCCCCTCCAGGC------------TGTGCTGACCATCGACAAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   -12            0.11%
CTCTCCCCTCCAGGC------------TGTGCTGACCATCGACAAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   -12            0.72%
CTCTCCCCTCCAGGCCGTGCATAAGGCTGTGCTGACCATCGACAAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   WT           84.7%
CTCTCCCCTCCAGGCCGTGCATAAaGCTGTGCTGACCATCGACgAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   Precise    8.68%
CTCTCCCCTCCAGGCCGTGC------------TGACCATCGACAAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   -12            0.81%
CTCTCCCCTCCAGGCCGTGC--------------------------------------------------------------------------------CCCCCCGA   -80            0.67%
PE2*
CTCTCCCCTCCAGGCCGTGCATAAaGCTGTGCTGACCATCGACgAGA--------------------GCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   -20            0.43%
CTCTCCCCTCCAGGCC---------------------------------------------------------------------ATACCCATGTCTATCCCCCCCGA   -69            0.26%
CTCTCCCCTCCAGGCCGTGCcATAAaGCTGTGCTGACCATCGACAAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   +1             0.11%
CTCTCCCCTCCAGGCCGTGCATAAGGCTGTGCTGAGCATCGACAAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   sub           0.07%
CTCTCCCCTCCAGGCCGTGCATAAGGCTGTGCTGACCATCGACgAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   sub           0.06%
CTCTCCCCTCCAGGCCGTGCATAAaGCTGTGCTGACCATCGACAAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   sub           0.04%
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Figure S6
a
GGCCGTGCATAAaGCTGTGCTGACCATCGACtAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   sub      0.25%
GGCCGTGCATAAGGCTGTGCTGACCATCGACAAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   WT       93.04%
GGCCGTGCATAAaGCTGTGCTGACCATCGACgAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   Precise  3.39%
GGCCGTGCATAAaGCTGTGCTGACCATCGACAAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   sub      0.51%
GGCCGTGC--------------------------------------------------------------------------------CCCCCCGA   -80      0.04%
GGCCGTG------------------------------------------------------------------------------GATTGAACAAA   -119     0.02%
GGCCGTGCATAAaGCTGTGCTGACCATCGACAAGAAAGtGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   sub      0.12%
GGCCGTGCATAAaGCTGTGCTGACCATtGAtGAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   sub      0.21%
GGCCGTGC------------TGACCATCGACAAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   -12      0.05%
GGCCGTGC-TAAGGCTGTGCTGACCATCGACAAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGA   -1       0.02%






S45 deletion (via TCC deletion)
GAAAAGCTGCTGTCAGCCACTGGCAGCAGCAGTCTTACTTGGATTCTGGAATCCATTCTGGTGCCACCACCACAGCTCCTTCCCTGAGTGGCAAGGGCAACCCT       WT       2026/45539
GAAAAGCTGCTGTCAGCCACTGGCAGCAGCAGTCTTACTTGGATTCTGGAATCCATTCTGGTGCCACCACCACAGCTCCT---CTGAGTGGCAAGGGCAACCCT       Precise  42153/45539
[63bp]------------------------------------ACTTGGATTCTGGAATCCATTCTGGTGCCACCACCACAGCTCCTTCCCTGAGTGGCAAGGGCAACCCT       -99      12/45539  
GAAAAGCTGCTGTCAGCCACTGGCAGCAGCAGT-----------------------------------------------------------------------[7bp]  -78      14/45539
GAAAAGCTGCTGTCAGCCACTGGCAGCAGCAGTCTTACTTGGATTCTGGAATCCATTCTGGTGCCACCA-----------------------------------[39bp] -74      16/45539
GAAAAGCTGCTGTCAGCCACTGGCAGCAGCAGTCTTACTTGGATTCTGGAATCCATTCTGGTGCCACCACCACAGCTC--------------------------[15bp] -41      12/45539















GGCCGTGCATAAGGCTGTGCTGACCATCGACAAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGAGG        WT     (72173/78458)  91.9   
GGCCGTGCATAAaGCTGTGCTGACCATCGACgAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGAGG        Precise(2115/78458)   2.70   0.034
GGCCGTGCATAAaGCTGTGCTGACCATCGACAAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGAGG        sub    (137/78458)    0.17   0.036
GGCCGTGCATAAaGCTGTGCTGACCATCGACtAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGAGG        sub    (115/78458)    0.15   0.045
GGCCGTGCATAAaGCTGTGCTGACCATtGAtgAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGAGG        sub    (89/78458)     0.11   0.049
GGCCGTGCATAAaGCTGTGCTGACCATCGAtAAGAAAGtGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGAGG        sub    (51/78458)     0.07   0.036
GGCCGTG-------------------------------------------------------------------------------------------[7bp]   -98    (73/78458)     0.09   0.034
GGCCGTG-------------------------------------------------------------------------------------------[31bp]  -119   (15/78458)     0.02   0.036
GGCCGTGC-TAAGGCTGTGCTGACCATCGACAAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGAGG        -1     (29/78458)     0.04   0.034
[12bp]-------------------------------------------------------------------GAGGCCATACCCATGTCTATCCCCCCCGAGG        -79    (13/78458)     0.02   0.036
GGCCGTGCATAAaGCTGTGCTGACCATCGACgAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTT--------------------------------[50bp]  -72    (12/78458)     0.02   0.034
[13bp]--------------------------------------------------------------------------------------------------[50bp]  -162   (18/78458)     0.02   0.049
GGCC---------------------------------------------------------------------ATACCCATGTCTATCCCCCCCGAGG        -69    (8/78458)      0.01   0.045
[12bp]----------------------------------------------------------------------------------TCTATCCCCCCCGAGG        -95    (6/78458)      0.01   0.057
GGCCGTGCATAAGGCTGTGCTGACCATCGACAAGAAAGGGACTGAAG---------------------------------------------------[5bp]   -56    (8/78458)      0.01   0.148
[8bp]--------------------------------------------------------------------------------------------------[80bp]  -186   (9/78458)      0.01   0.085
G--------------------------------------------------------------------------------------------CGAGG        -92    (3/78458)      0.00   0.144
[12bp]--------------------------------------------------------------------------------------------------[868bp] -978   (3/78458)      0.00   0.176
[2316bp]--------------------------------------------------------------------------------------------------[28bp]  -2442  (2/78458)      0.00   0.144
UMI/Total UMI
UDiTaS
Deletions spaning pegRNA and nicking sgRNA (>100bp)
Deletions between pegRNA and nicking sgRNA (<100bp)
GGCCGTGC------------TGACCATCGACAAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGAGG        -12    (19/78458)     0.02   0.036
GGCCGTGC------------------------------------------------------------------------------CCCCCCCGAGG        -80    (4/78458)      0.01   0.071      
Scaffold insertion
GGCCGTGCATAAaGCTGTGCTGACCATCGACgAGAgAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGAGG        Precise(12/78458)     0.02




.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted December 16, 2020. ; https://doi.org/10.1101/2020.12.15.422970doi: bioRxiv preprint 
